News
The spin-off Aptadel selected to be part of BCN Health Booster
Aptadel comprise the first generation of companies accelerated at the BCN Health Booster, an initiative promoted by the University of Barcelona (UB), Barcelona Science Park (PCB) and the Barcelona City Council, with support from Barcelona Activa and collaboration from Biocat. The project was created under the Barcelona Science Plan and is an example of collaboration […]
The activation of a key protein completes the process of death by apoptosis in glioblastoma cells
Apoptosis is the mechanism by which defective cells in the body promote their own death in order to protect the body. It is a complex process, with many stages, during which the different parts of the cell are degraded. In glioblastoma cells, however, although apoptosis begins, it stops at one of the stages, allowing the […]
New tool to assess epilepsy cases that need surgery
The best known symptom of epilepsy are seizures, more or less recurrent, which may or may not be accompanied by convulsions. In the case of temporal lobe epilepsy, these episodes are caused by an excessive increase in nerve discharges in a certain area of the temporal lobe of the brain. The main form of treatment […]
IDIBELL is committed to innovation on its 2nd Career Day
During the afternoon of last Thursday, November 18 and the morning of Friday, November 19, the second edition of Career Day was held, organized by IDIBELL with the support of the ICO, the University of Barcelona, the Bellvitge University Hospital and the Hospital de Viladecans. This event brought together professionals from the fields of research […]
Xavier Bosch, winner of the Maurice Hilleman award for his contribution to the papillomavirus vaccine
Doctor and researcher Xavier Bosch has been selected this year as the winner of the the International Papillomavirus Society‘s Maurice Hilleman Award. The award, announced on 19 November, acknowledges the professional career and contribution to the development and promotion of the vaccines against this kind of virus. Bosch, principal investigator at the Bellvitge Biomedical Research Institute (IDIBELL), emeritus researcher at the Catalan Institute of […]
The first gene therapy approach for MLC leukoencephalopathy, designated as an orphan drug
The gene therapy approach designated as orphan drug has reduced the symptoms of MLC in the pre-clinical phase in model mice of the disease.
IDIBELL offers 10 projects for incoming INPhINIT fellowships
La Caixa Foundation concedes 35 fellowships for early-stage researchers of any nationality to pursue their PhD studies in the best Spanish and Portuguese research centres and units with excellence distinction: Spanish Seal of Excellence Severo Ochoa, María de Maeztu or Health Institute Carlos III and Portuguese units accredited as “excellent” by the Fundação de Ciência […]
AELAM donates 21.000€ to research on lymphangioleiomyomatosis
A representation from AELAM (Spanish Association of Lymphangioleiomyomatosis) delivered a donation of 21.000€ for the research on this disease. This collaboration will be used, among others, to develop a screening project for new therapeutic strategies for lymphangioleiomyomatosis (LAM). The act of delivery took place in the Duran i Reynals Hospital and counted on the attendance of the Bellvitge Institute of […]
IDIBELL receives more than one and a half million euros from AECC to fund cancer research projects
The Spanish Association Against Cancer (AECC) distributes every year a large amount of financial aid for cancer research with the ultimate goal of bringing scientific results closer to patients, which would result in an improvement in early detection of cases and their quality of life and an increase in their survival. At IDIBELL, cancer is […]